HPLC-fluorescence assay for acyclovir in children

Biomedical Chromatography

Volumn 22, Issue 8, 2008, Pages 879-887

  Zeng, L ^a,b   Nath, Christan E ^b   Shaw, P J ^b   Earl, J W ^b   McLachlan, A J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c ANZAC Research Institute   (Australia)

Author keywords

Acyclovir; Children; Fluorescence; HPLC; Pharmacokinetics

Indexed keywords

PEDIATRICS; SODIUM COMPOUNDS; VIRUSES;

ACYCLOVIR; CHILD; FLUORESCENCE ASSAY; GUANOSINES; HPLC; HPLC METHOD; HUMAN PLASMAS; INTERNAL STANDARDS; PROTEIN PRECIPITATION; SIMPLE++;

FLUORESCENCE;

ACETONITRILE; ACICLOVIR; AMPHOTERICIN B; BUSULFAN; CARBOPLATIN; CYCLOSPORIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GUANOSINE; MELPHALAN; MYCOPHENOLIC ACID; PERCHLORIC ACID; SODIUM DIHYDROGEN PHOSPHATE; TETRABUTYLAMMONIUM;

ACCURACY; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CENTRIFUGATION; CHILD; CHILD CARE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG RETENTION; DRUG STRUCTURE; FLUORESCENCE; HUMAN; INFANT; PRECIPITATION; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; SUPERNATANT; VALIDATION PROCESS;

EID: 50049134069     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1006     Document Type: Article

References (33)

1. Bahrami G, Mirzaeei S and Kiani A. Determination of acyclovir in human serum by high-performance liquid chromatography using liquid-liquid extraction and its application in pharmacokinetic studies. Journal of Chromatography B 2005; 816: 327-331.
2. Bangaru RA, Barisal YK, Rao AR and Gandhi TP. Rapid, simple and sensitive high-performance liquid chromatographic method for detection and determination of acyclovir in human plasma and its use in bioavailability studies. Journal of Chromatography B 2000; 739: 231-237.
3. Basavaiah K, Prameela HC and Chandrashekar U. Simple high-performance liquid chromatographic method for the determination of acyclovir in pharmaceuticals. Farmaco 2003; 58: 1301-1306.
4. Bleyzac N, Barou P, Massenavette B, Contamin B, Maire P, Berthier JC and Aulagner G. Assessment of acyclovir intraindividual pharmacokinetic variability during continuous hemofiltration, continuous hemodiafiltration, and continuous hemodialysis. Therapeutic Drug Monitoring 1999; 21: 520-525.
5. Blum MR, Liao SH and de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. The American Journal of Medicine 1982; 73: 186-192.
6. Boulieu R, Gallant C and Silberstein N. Determination of acyclovir in human plasma by high-performance liquid chromatography. Journal of Chromatography B 1997; 693: 233-236.
7. Caamano MM, Garcia LV, Elorza B and Chantres JR. Improved RPLC determination of acyclovir using hexylamine as silanol masking agent. Journal of Pharmaceutical and Biomedical Analysis 1999; 21: 619-624.
8. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L and Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proceedings of the National Academy of Sciences of the United States of America 1977; 74: 5716-5720.
9. Fernandez M, Sepulveda J, Aranguiz T and von Plessing C. Technique validation by liquid chromatography for the determination of acyclovir in plasma. Journal of Chromatography B 2003; 791: 357-363.
10. Fletcher C and Bean B. Evaluation of oral acyclovir therapy. Drug Intelligence and Clinical Pharmacy 1985; 19: 518-524.
11. Jankowski A, Jankowska AL and Lamparczyk H. Determination and pharmacokinetics of acyclovir after ingestion of suspension form. Journal of Pharmaceutical and Biomedical Analysis 1998; 18: 249-254.
12. Kishino S, Takekuma Y, Sugawara M, Shimamura T, Furukawa H, Todo S and Miyazaki K. Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. Journal of Chromatography B 2002; 780: 289-294.
13. Laskin O. Clinical pharmacokinetics of acyclovir. Clinical Pharmacokinetics 1983; 8: 187-201.
14. Loregian A, Gatti R, Palu G and De Palo EF. Separation methods for acyclovir and related antiviral compounds. Journal of Chromatography B 2001; 764: 289-311.
15. Mascher H, Kikuta C, Metz R and Vergin H. New, high-sensitivity high-performance liquid chromatographic method for the determination of acyclovir in human plasma, using fluorometric detection. Journal of Chromatography 1992; 583: 122-127.
16. McMullin CM, Kirk B, Sunderland J, White LO, Reeves DS and MacGowan AP. A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum. The Journal of Antimicrobial Chemotherapy 1996; 38: 739-740.
17. Nebinger P and Koel M. Determination of acyclovir by ultrafiltration and high-performance liquid chromatography. Journal of Chromatography B 1993; 619: 342-344.
18. O'Brien JJ and Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989; 37: 233-309.
19. Peh KK and Yuen KH. Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection. Journal of Chromatography B 1997; 693: 241-244.
20. Perry CM and Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52: 754-772.
21. Pham-Huy C, Stathoulopoulou F, Sandouk P, Scherrmann JM, Palombo S and Girre C. Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution. Journal of Chromatography B 1999; 732: 47-53.
22. Phan DD, Chin-Hong P, Lin ET, Anderle P, Sadee W and Guglielmo BJ. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrobial Agents and Chemotherapy 2003; 47: 2351-2353.
23. Poirier JM, Radembino N and Jaillon P. Determination of acyclovir in plasma by solid-phase extraction and column liquid chromatography. Therapeutic Drug Monitoring 1999; 21: 129-133.
24. Riley CM, Ault JM Jr and Klutman NE. Chromatographic methods for the bioanalysis of antiviral agents. Journal of Chromatography 1990; 531: 295-368.
25. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ and Collins P. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978; 272: 583-585.
26. Svensson JO, Barkholt L and Sawe J. Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. Journal of Chromatography B 1997; 690: 363-366.
27. Swart KJ, Hundt HK and Groenewald AM. Automated high-performance liquid chromatographic method for the determination of acyclovir in plasma. Journal of Chromatography A 1994; 663: 65-69.
28. Tadepalli SM, Quinn RP and Averett DR. A competitive enzyme-linked immunosorbent assay to quantitate acyclovir and BW B759U in human plasma and urine. Antimicrobial Agents and Chemotherapy 1986; 29: 93-98.
29. Teshima D, Otsubo K, Yoshida T, Itoh Y and Oishi R. A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography. Biomedical Chromatography 2003; 17: 500-503.
30. Tzanavaras PD and Themelis DG. High-throughput HPLC assay of acyclovir and its major impurity guanine using a monolithic column and a flow gradient approach. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 1526-1530.
31. Vo HC, Henning PA, Leung DT and Sacks SL. Development and validation of a plasma assay for acyclovir using high-performance capillary electrophoresis with sample stacking. Journal of Chromatography B 2002; 772: 291-297.
32. Volpato NM, Santi P, Laureri C and Colombo P. Assay of acyclovir in human skin layers by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 1997; 16: 515-520.
33. Wood MJ, McKendrick MW, Freris MW, Jeal SC, Jones DA and Gilbert AM. Trough plasma acyclovir concentrations and safety and of oral acyclovir, 800 mg five times daily for 7 days in elderly patients with herpes zoster. The Journal of Antimicrobial Chemotherapy 1994; 33: 1245-1249.